Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2025)

Amylyx Pharmaceuticals has reported Non-Current Assets over the past 5 years, most recently at $9.0 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $9.0 million for Q4 2025, up 113.56% from a year ago — trailing twelve months through Dec 2025 was $29.6 million (up 34.33% YoY), and the annual figure for FY2025 was $9.0 million, up 113.56%.
  • Non-Current Assets for Q4 2025 was $9.0 million at Amylyx Pharmaceuticals, down from $9.4 million in the prior quarter.
  • Over the last five years, Non-Current Assets for AMLX hit a ceiling of $52.8 million in Q4 2023 and a floor of $663000.0 in Q4 2021.
  • Median Non-Current Assets over the past 5 years was $9.0 million (2025), compared with a mean of $12.9 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 1305.73% in 2022 and later crashed 92.04% in 2024.
  • Amylyx Pharmaceuticals' Non-Current Assets stood at $663000.0 in 2021, then skyrocketed by 1305.73% to $9.3 million in 2022, then surged by 466.39% to $52.8 million in 2023, then crashed by 92.04% to $4.2 million in 2024, then surged by 113.56% to $9.0 million in 2025.
  • The last three reported values for Non-Current Assets were $9.0 million (Q4 2025), $9.4 million (Q3 2025), and $7.7 million (Q2 2025) per Business Quant data.